Показано 0 из 0
Дата |
---|
18:36 |
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
8.80
|
9.92
|
8.72
|
8.72
|
8.72
|
8.72
|
|
|
|
|
8.70
|
9.74
|
8.80
|
8.80
|
8.80
|
8.80
|
|
|
|
|
8.78
|
9.88
|
8.86
|
8.86
|
8.86
|
8.86
|
|
|
|
|
8.84
|
9.92
|
8.52
|
8.52
|
8.52
|
8.52
|
|
|
|
|
8.50
|
9.56
|
7.94
|
7.94
|
7.94
|
7.94
|
|
|
|
|
8.32
|
9.56
|
8.32
|
8.32
|
8.32
|
8.32
|
|
|
|
|
8.30
|
9.28
|
8.34
|
8.34
|
8.34
|
8.34
|
|
|
|
|
8.32
|
9.32
|
8.32
|
8.32
|
8.32
|
8.32
|
|
|
|
|
8.30
|
9.28
|
8.28
|
8.28
|
8.28
|
8.28
|
|
|
|
|
8.26
|
9.26
|
8.46
|
8.46
|
8.46
|
8.46
|
|
|
|
|
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase II (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase Ib (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).